Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$5.30 -0.4%	$4.67	$1.00 ▼ $7.00	$47.01M	0.67	230,283 shs	39,837 shs
BIVI BioVie	$1.67 -6.7%	$8.45	$1.52 ▼ $75.00	$3.11M	0.7	90,157 shs	292,627 shs
NRXP NRx Pharmaceuticals	$2.39 +3.0%	$3.10	$1.10 ▼ $6.01	$41.32M	1.59	502,662 shs	344,866 shs
RENB Renovaro	$0.24 -0.3%	$0.31	$0.22 ▼ $2.10	$40.84M	0.54	2.21 million shs	566,251 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	-1.48%	+2.11%	+15.90%	+28.19%	+325.60%
BIVI BioVie	+7.19%	-70.17%	-74.93%	-83.27%	-92.78%
NRXP NRx Pharmaceuticals	-7.94%	-14.71%	-27.73%	+1.31%	+14.85%
RENB Renovaro	-3.37%	-6.81%	-11.81%	-28.97%	-61.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	1.6218 of 5 stars	3.3	3.0	0.6	1.7	0.0
BIVI BioVie	0.3439 of 5 stars	0.0	2.0	2.5	0.0	0.6
NRXP NRx Pharmaceuticals	3.2155 of 5 stars	3.6	5.0	2.8	0.8	0.6
RENB Renovaro	0.9614 of 5 stars	0.0	3.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	126.42% Upside
BIVI BioVie	4.00	Strong Buy	N/A	N/A
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	1,092.47% Upside
RENB Renovaro	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BIVI, NRXP, RENB, and ATHE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/4/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
BIVI BioVie	N/A	N/A	N/A	N/A	$25.35 per share	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	$0.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
BIVI BioVie	-$32.12M	-$79.10	N/A	∞	N/A	N/A	-100.88%	-78.49%	8/21/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)
RENB Renovaro	-$88.43M	-$0.77	N/A	∞	N/A	N/A	-60.38%	-47.04%	9/29/2025 (Estimated)

Latest BIVI, NRXP, RENB, and ATHE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/12/2025	Q3 2025	BIVI BioVie	-$3.20	-$1.50	+$1.70	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
BIVI BioVie	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
BIVI BioVie	N/A	9.31	9.31
NRXP NRx Pharmaceuticals	N/A	0.22	0.22
RENB Renovaro	N/A	0.13	0.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
BIVI BioVie	4.59%
NRXP NRx Pharmaceuticals	4.27%
RENB Renovaro	71.41%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
BIVI BioVie	2.39%
NRXP NRx Pharmaceuticals	19.00%
RENB Renovaro	0.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
BIVI BioVie	10	1.86 million	1.82 million	No Data
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable
RENB Renovaro	20	172.12 million	171.26 million	Optionable

BIVI, NRXP, RENB, and ATHE Headlines

Recent News About These Companies

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

August 8, 2025 | accessnewswire.comA

Renovaro Biosciences Granted Nasdaq Compliance Extension

August 6, 2025 | tipranks.com

AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks

July 30, 2025 | tmcnet.com

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

July 28, 2025 | accessnewswire.comA

Renovaro (NASDAQ:RENB) Trading 0.1% Higher - Time to Buy?

July 23, 2025 | marketbeat.com

Renovaro Biosciences: Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

July 17, 2025 | finanznachrichten.de

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

July 17, 2025 | accessnewswire.comA

Renovaro Biosciences Receives Nasdaq Compliance Notice

July 14, 2025 | tipranks.com

Renovaro Strengthens Balance Sheet Through Debt ... - Morningstar

July 11, 2025 | morningstar.comM

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

July 9, 2025 | accessnewswire.comA

Renovaro Biosciences Restructures Debt with Exchange Agreement

July 9, 2025 | tipranks.com

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - Nasdaq

July 2, 2025 | nasdaq.com

Renovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

June 30, 2025 | accessnewswire.comA

Renovaro subsidiary secures patent for drug discovery AI

June 5, 2025 | uk.investing.com

RENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingen

June 5, 2025 | nl.investing.com

RENB stock touches 52-week low at $0.27 amid market challenges

June 5, 2025 | investing.com

Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics

June 5, 2025 | msn.com

Renovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkeling

June 3, 2025 | nl.investing.com

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

June 3, 2025 | globenewswire.com

Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement

May 24, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI, NRXP, RENB, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$5.30 -0.02 (-0.38%)

Closing price 03:59 PM Eastern

Extended Trading

$5.28 -0.02 (-0.38%)

As of 04:10 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

BioVie NASDAQ:BIVI

$1.67 -0.12 (-6.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 +0.04 (+2.10%)

As of 05:33 PM Eastern

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

NRx Pharmaceuticals NASDAQ:NRXP

$2.39 +0.07 (+3.02%)

Closing price 04:00 PM Eastern

Extended Trading

$2.44 +0.04 (+1.88%)

As of 05:21 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Renovaro NASDAQ:RENB

$0.24 0.00 (-0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$0.24 +0.00 (+1.14%)

As of 05:25 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time